ADIL Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Adial Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.99 |
| 52 Week High | US$4.17 |
| 52 Week Low | US$0.77 |
| Beta | 1.3 |
| 11 Month Change | -4.71% |
| 3 Month Change | 0.20% |
| 1 Year Change | -53.47% |
| 33 Year Change | -98.50% |
| 5 Year Change | -97.15% |
| Change since IPO | -99.02% |
Recent News & Updates
Recent updates
Adial Clinical Trial: A Fluff Or A Win?
Aug 22Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01
Aug 16Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst
Jun 21Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate
Jan 11Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital
Nov 25Shareholder Returns
| ADIL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.8% | 3.4% | 1.6% |
| 1Y | -53.5% | 14.2% | 32.3% |
Return vs Industry: ADIL underperformed the US Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: ADIL underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| ADIL volatility | |
|---|---|
| ADIL Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ADIL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ADIL's weekly volatility has decreased from 25% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 6 | Cary Claiborne | www.adialpharma.com |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders.
Adial Pharmaceuticals, Inc. Fundamentals Summary
| ADIL fundamental statistics | |
|---|---|
| Market cap | US$6.41m |
| Earnings (TTM) | -US$13.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs ADIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADIL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.03m |
| Earnings | -US$13.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.03 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ADIL perform over the long term?
See historical performance and comparison